The insider sales are routine profit-taking following deep-in-the-money option exercises. At 0.015% of market cap, this cluster carries no bearish signal. The strong historical win rate (86% T+20) on prior RVMD reports reflects the company's positive momentum, not insider selling patterns. Monitor for any 10b5-1 plan adoption or further acceleration of sales, but this filing alone does not warrant action.
Price Chart
Executive Summary
Two insiders at Revolution Medicines executed a cluster of open-market sales totaling ~$6.5M over three days, with the bulk from C-suite executive Anthony Mancini ($3.15M) and director Lorence Kim ($3.59M). The sales follow option exercises by Mancini at $33.62/share, locking in massive gains at current ~$205 prices. At a $43.7B market cap, the total represents ~0.015% — well below the 0.1% materiality threshold — making this a routine liquidity event rather than an informed bearish signal. The cluster is amplified by the cross-filing insider-trades context, but the proportionality check overrides: the dollar amount is trivial relative to company size.
Key Financial Metrics
Key Facts
- Anthony Mancini (C-suite) sold 15,448 shares for ~$3.15M on Sep 10 after exercising options at $33.62/share
- Lorence Kim (Director) sold 17,090 shares for ~$3.59M on Sep 8
- Total open-market sales: ~$6.5M, representing ~0.015% of $43.7B market cap
- Mancini also exercised 9,363 shares at $0 (non-cash) on Sep 10
- No open-market purchases in the cluster — net direction is selling
Financial Impact
~$6.5M in insider sales, ~0.015% of market cap — trivial
Risk Factors
- Insider selling could accelerate if the stock continues to rally
- Option exercises followed by sales may signal insiders view current valuation as full
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RVMD-1789425868525 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access